<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180630040291N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-09-09</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of rTMS on Amphetamine craving</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of rTMS on amphetamine craving in patients with amphethamine dependency</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/32327</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Restricted randomization based on random allocation rule, Blinding description: Using sham coil.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Amphethamine craving.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The patients will be selected among clients referring to the addiction clinic (MMT) of Tehran Psychiatric Hospital and Tehran Behavioral Sciences Institute, and Iran's Psychiatric Center using convenient sampling method.   The research inclusion criteria included 1- People aged 18 to 60 years who have the amphetamines dependence criteria based on DSM-V before the treatment and have undergone treatment and have not used amphetamine at least for 2 weeks 2- The patient report the methamphetamine craving. Exclusion criteria included: Current psychosis, Other substance dependency except for nicotine and caffeine,  Contraindication of rTMS, Recent change of medication in past two weeks. Intervention 2: Intervention group: The patients will be selected among clients referring to the addiction clinic (MMT) of Tehran Psychiatric Hospital and Tehran Behavioral Sciences Institute, and Iran's Psychiatric Center using convenient sampling method.   The research inclusion criteria included 1- People aged 18 to 60 years who have the amphetamines dependence criteria based on DSM-V before the treatment and have undergone treatment and have not used amphetamine at least for 2 weeks 2- The patient report the methamphetamine craving.Exclusion criteria included: Current psychosis, Other substance dependency except for nicotine and caffeine,  Contraindication of rTMS, Recent change of medication in past two weeks. Intervention 3: Control group: The patients will be selected among clients referring to the addiction clinic (MMT) of Tehran Psychiatric Hospital and Tehran Behavioral Sciences Institute, and Iran's Psychiatric Center using convenient sampling method.   The research inclusion criteria included 1- People aged 18 to 60 years who have the amphetamines dependence criteria based on DSM-V before the treatment and have undergone treatment and have not used amphetamine at least for 2 weeks 2- The patient report the methamphetamine craving. Exclusion criteria included: Current psychosis, Other substance dependency except for nicotine and caffeine,  Contraindication of rTMS, Recent change of medication in past two weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Original article

When:
At the end of the project

To whom:
The readers of the journal in which the article will be accepted

Conditions:
Guideline of the journal

Where to obtain:
It is not determined yet

How to obtain:
Guideline of the journal

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Atefeh Ghanbari Jolfaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasoul akram hospital, Niayesh St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 6651 9519</telephone>
        <email>draghj@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Atefeh Ghanbari Jolfaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasoul akram hospital, Niayesh St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6651 9519</telephone>
        <email>draghj@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being right handed, Having DSM-IV criteria of amphethamine dependency, At least two weeks of amphethamine withdrawal; Having amphethamine craving</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Current psychosis, Other substance dependency except for nicotine and caffeine,  Contraindication of rTMS, Recent change of medication in past two weeks</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F19.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other psychoactive substance abuse</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The patients will be selected among clients referring to the addiction clinic (MMT) of Tehran Psychiatric Hospital and Tehran Behavioral Sciences Institute, and Iran's Psychiatric Center using convenient sampling method.   The research inclusion criteria included 1- People aged 18 to 60 years who have the amphetamines dependence criteria based on DSM-V before the treatment and have undergone treatment and have not used amphetamine at least for 2 weeks 2- The patient report the methamphetamine craving. Exclusion criteria included: Current psychosis, Other substance dependency except for nicotine and caffeine,  Contraindication of rTMS, Recent change of medication in past two weeks</i_keyword>
      <i_keyword>Intervention group: The patients will be selected among clients referring to the addiction clinic (MMT) of Tehran Psychiatric Hospital and Tehran Behavioral Sciences Institute, and Iran's Psychiatric Center using convenient sampling method.   The research inclusion criteria included 1- People aged 18 to 60 years who have the amphetamines dependence criteria based on DSM-V before the treatment and have undergone treatment and have not used amphetamine at least for 2 weeks 2- The patient report the methamphetamine craving.Exclusion criteria included: Current psychosis, Other substance dependency except for nicotine and caffeine,  Contraindication of rTMS, Recent change of medication in past two weeks</i_keyword>
      <i_keyword>Control group: The patients will be selected among clients referring to the addiction clinic (MMT) of Tehran Psychiatric Hospital and Tehran Behavioral Sciences Institute, and Iran's Psychiatric Center using convenient sampling method.   The research inclusion criteria included 1- People aged 18 to 60 years who have the amphetamines dependence criteria based on DSM-V before the treatment and have undergone treatment and have not used amphetamine at least for 2 weeks 2- The patient report the methamphetamine craving. Exclusion criteria included: Current psychosis, Other substance dependency except for nicotine and caffeine,  Contraindication of rTMS, Recent change of medication in past two weeks</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Amphetamine craving. Timepoint: Before rTMS and at least 1 week after the end of rTMS. Method of measurement: VAS  Visual cue_indused craving assessment.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Number of hospitalizations. Timepoint: Six months after rTMS. Method of measurement: Counting.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-01-15</approval_date>
        <contact_name>Iran University of Medical Sciencs</contact_name>
        <contact_address>Hemmat highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
